Table 4.
Association of ever use of individual bisphosphonates with the risk of hip fracture
| Cases | Controls | Average duration | Time since first prescription | Model 1 | Model 2 | |
|---|---|---|---|---|---|---|
| n (%) | n (%) | (days) | (days) | OR (95% CI) | OR (95% CI) | |
| Never use | 1726 (85.9) | 8838 (88.0) | – | – | 1 (ref.) | 1 (ref.) |
| Alendronate | 128 (6.4) | 598 (6.0) | 599 (566) | 956 (603) | 1.10 (0.90 to 1.34) | 0.99 (0.81 to 1.22) |
| Risedronate | 95 (4.7) | 438 (4.4) | 508 (459) | 822 (503) | 1.12 (0.89 to 1.41) | 1.02 (0.81 to 1.30) |
| Etidronate | 19 (1.0) | 63 (0.6) | 818 (629) | 1478 (746) | 1.55 (0.92 to 2.59) | 1.56 (0.91 to 2.65) |
| Ibandronate | 7 (0.4) | 9 (0.1) | 161 (137) | 239 (151) | 4.18 (1.55 to 11.2) | 3.67 (1.31 to 10.3) |
| Switcher | 34 (1.7) | 99 (1.0) | 898 (676) | 1397 (714) | 1.80 (1.21 to 2.68) | 1.63 (1.07 to 2.47) |
Model 1: Conditional logistic regression model.
Model 2: Conditional logistic regression model adjusted for smoking, body mass index, and alcoholism, previous fracture, kidney disease, malabsorption, stroke, dementia, rheumatoid arthritis, diabetes, epilepsy, Parkinson's disease, and thyroid disease, PPI (no use, ≤1 year, >1 year), anxiolytics, sedatives, antidepressants, antihypertensives, oral corticosteroids (no use, ≤1 year, >1 year), raloxifene, hormone replacement therapy and thiazolidinediones.